How do you tell SLE arthritis from rheumatoid arthritis on Step 1?

SLE arthritis is classically a symmetric inflammatory arthritis that is non-erosive. The key distinction from rheumatoid arthritis is that patients can have joint pain, stiffness, and even deformities from tendon or ligament laxity, but X-rays do not show erosions. This makes a vignette with inflammatory hand or wrist symptoms plus multi-organ findings point more toward SLE than RA.

Why does SLE cause low complement levels?

SLE causes low complement because it is driven by immune complex deposition with complement activation. Autoantibodies form against nuclear antigens, the antigen-antibody complexes circulate and deposit in tissues such as the kidneys, skin, joints, and serosal surfaces, and complement is then consumed during the inflammatory response. Low C3 and C4 are especially associated with active disease, particularly lupus nephritis.

Which antibodies are most useful for diagnosing SLE?

ANA is the best screening test, while anti-dsDNA and anti-Smith are the classic confirmatory antibodies. ANA is highly sensitive but not specific, so false positives are common. Anti-dsDNA has high specificity and also correlates with lupus nephritis and disease activity. Anti-Smith is the most specific antibody for SLE, making it especially high-yield for confirming the diagnosis.

What clue should make you think of lupus nephritis?

Proteinuria, hematuria, and RBC casts should make you think of lupus nephritis. In SLE, kidney involvement may also present with edema, hypertension, or an incidental abnormal urinalysis. Anti-dsDNA antibodies and low C3 and C4 further support active immune complex disease affecting the kidneys. If nephritis is suspected, kidney biopsy is used to determine the class and guide treatment intensity.

What is the first-line treatment for most patients with SLE?

Hydroxychloroquine is baseline treatment for most patients with SLE. It is used for skin and joint symptoms and also helps prevent flares. NSAIDs can be added for mild inflammatory joint pain, while systemic glucocorticoids and immunosuppressants are used for more severe or organ-threatening disease. A key adverse effect of hydroxychloroquine is retinopathy, so patients need eye exams.

Everything You Need to Know About SLE (systemic lupus erythematosus) for Step 1

Systemic lupus erythematosus (SLE) is one of those Step 1 “great imitators” that can look like anything—rash, arthritis, kidney failure, seizures, cytopenias—yet it’s built on a few repeatable, testable immune mechanisms. If you anchor SLE to its autoantibodies, immune complex deposition, and a handful of classic clinical patterns, you’ll stop memorizing random facts and start recognizing vignettes instantly.

Where SLE Fits in MSK (Bone & Joint Disorders)

Even though SLE is a systemic autoimmune disease, it’s extremely testable in the MSK bucket because it commonly presents with:

Inflammatory, symmetric arthralgias/arthritis (often hands/wrists)
Non-erosive arthritis (key distinction vs rheumatoid arthritis)
Tendon/ligament laxity → reducible deformities (Jaccoud arthropathy)

💡

Step framing: SLE = autoimmune + immune complex disease that frequently shows up as a joint complaint plus multi-organ clues.

Definition (What SLE Is)

Systemic lupus erythematosus is a chronic, relapsing-remitting autoimmune disease characterized by:

Loss of self-tolerance → autoantibody production
Type III hypersensitivity: immune complex deposition → inflammation and tissue damage
Some manifestations are also Type II hypersensitivity (antibody-mediated cytopenias)

High-yield epidemiology:

Classically affects women of childbearing age
Higher prevalence/severity in African American and Hispanic populations (commonly tested association)

Pathophysiology (How It Happens)

Core immune mechanism: immune complexes (Type III)

Autoantibodies form against nuclear antigens (DNA, histones, Sm, RNP)
Antigen–antibody complexes circulate
Deposition occurs in:
- Kidneys (glomeruli)
- Skin
- Joints
- Serosal surfaces (pleura/pericardium)
Complement is activated → inflammation
→ low complement levels (consumption)

High-yield lab consequence:

Low C3 and C4 during active disease (esp. nephritis)

Why SLE makes autoantibodies (Step 1-friendly explanation)

Defective clearance of apoptotic debris → nuclear antigens persist
Increased exposure of nuclear material to immune system
B cell hyperactivity + T cell dysregulation → autoantibodies

Hypersensitivity types tested in SLE

Manifestation	Hypersensitivity Type	Classic Example
Nephritis, arthritis, rash, serositis	Type III	Immune complex deposition
Hemolytic anemia, thrombocytopenia, leukopenia	Type II	Autoantibodies against blood cells

Clinical Presentation (How It Shows Up on Step)

The “classic” symptom clusters

MSK

Symmetric arthralgia/arthritis
Non-erosive inflammatory arthritis
Morning stiffness can occur, but X-rays lack erosions (unlike RA)

Skin/Mucosa

Malar rash (spares nasolabial folds is a common teaching point)
Photosensitivity
Oral/nasal ulcers (often painless)

Kidney

Lupus nephritis: hematuria, proteinuria, RBC casts
May present as edema/HTN or incidental abnormal urinalysis

Serositis

Pleuritis or pericarditis (pleuritic chest pain, friction rub)

Neuro/Psych

Seizures, psychosis, cognitive dysfunction (varies)

Hematologic

Autoimmune hemolytic anemia, leukopenia, thrombocytopenia

High-yield “pattern recognition” clue list

If you see young woman + joint pain + rash + proteinuria → think SLE first.

Diagnosis (What Confirms It)

Screening vs specific antibodies (know the hierarchy)

Test	Sensitivity	Specificity	Step takeaway
ANA	High	Low	Great screening test; many false positives
Anti–dsDNA	Moderate	High	Correlates with lupus nephritis and disease activity
Anti-Smith (Sm)	Low	Very high	Most specific for SLE
Anti-histone	—	—	Suggests drug-induced lupus

💡

High-yield: ANA positive is common, but anti-dsDNA and anti-Sm are the classic Step 1 “confirmers.”

Complement and inflammatory markers

Low C3/C4 suggests active immune complex disease (often nephritis)
ESR may be elevated; CRP can be variable (CRP spikes more with infection—useful in differentials)

Renal evaluation (must-know for Step)

Urinalysis: proteinuria, hematuria, RBC casts
If nephritis suspected → kidney biopsy determines class and treatment intensity

Lupus nephritis classes (high-yield summary)

Class	Path	Key association
I	Minimal mesangial	Mild/normal LM
II	Mesangial proliferative	Mild hematuria/proteinuria
III	Focal proliferative	<50% glomeruli
IV	Diffuse proliferative	Most common & most severe; “wire-loop” lesions
V	Membranous	Nephrotic syndrome pattern
VI	Advanced sclerosing	ESRD

Wire-loop lesions = thickened capillary loops from subendothelial immune complex deposition (classic for Class IV).

Treatment (How You Manage It—Step 1 + Step 2 overlap)

Baseline management (most patients)

Hydroxychloroquine for skin/joint symptoms and flare prevention
- Key adverse effect: retinopathy (requires eye exams)
NSAIDs for mild inflammatory joint pain (watch kidneys/GI)

Moderate to severe flares / organ-threatening disease

Glucocorticoids (systemic) for significant inflammation
Steroid-sparing immunosuppressants depending on organ:
- Mycophenolate mofetil: common for lupus nephritis
- Cyclophosphamide: severe nephritis/CNS disease (toxicity-heavy)
- Azathioprine: maintenance in some cases

Biologics (high-yield mention)

Belimumab (anti-BAFF) can be used in refractory cases (often tested as “newer SLE drug”)

High-Yield Associations & Classic Vignette Traps

1) Drug-induced lupus (DIL)

Clues

Lupus-like symptoms after starting certain meds
Usually no renal/CNS involvement (classic teaching)
Labs: anti-histone antibodies

High-yield drugs (think “HIND”)

Hydralazine
Isoniazid
Nprocainamide (often written as Procainamide)
D-penicillamine (plus others like anti-TNF agents)

2) Antiphospholipid syndrome (APS) in SLE

Can coexist with SLE and is extremely testable.